Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of RC198 in Advanced Solid Tumors
NCT05867303Phase 1Active, not recruiting
- Sponsor
- RemeGen
- Start
- Jun 2023
- Primary completion
- Sep 2024
- Modality
- Fc-Fusion Proteins
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of RC198 in melanoma, urothelial carcinoma (UC), renal cell carcinoma (RCC) and 3 more, sponsored by RemeGen. Primary endpoints: Maximum Tolerated Dose, Recommended Phase 2 Dose and 1 more. Started Jun 2023; status: active, not recruiting.
02
Drugs
RC198
03
Conditions
melanomaurothelial carcinoma (UC)renal cell carcinoma (RCC)non-small cell lung cancer (NSCLC)head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT05867303.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05867303.